|
1
|
Lehmann T and Wrzesinski T: The molecular
basis of adrenocortical cancer. Cancer Genet. 205:131–137. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bilimoria KY, Shen WT, Elaraj D, Bentrem
DJ, Winchester DJ, Kebebew E and Sturgeon C: Adrenocortical
carcinoma in the United States: Treatment utilization and
prognostic factors. Cancer. 113:3130–3136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kutikov A, Mallin K, Canter D, Wong YN and
Uzzo RG: Effects of increased cross-sectional imaging on the
diagnosis and prognosis of adrenocortical carcinoma: Analysis of
the National Cancer Database. J Urol. 186:805–810. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patterson EE, Holloway AK, Weng J, Fojo T
and Kebebew E: MicroRNA profiling of adrenocortical tumors reveals
miR-483 as a marker of malignancy. Cancer. 117:1630–1639. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chiodini I: Clinical review: Diagnosis and
treatment of subclinical hypercortisolism. J Clin Endocrinol Metab.
96:1223–1236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kuruba R and Gallagher SF: Current
management of adrenal tumors. Curr Opin Oncol. 20:34–46. 2008.
View Article : Google Scholar
|
|
7
|
Maas S: Gene regulation through RNA
editing. Discov Med. 10:379–386. 2010.PubMed/NCBI
|
|
8
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Etheridge A, Lee I, Hood L, Galas D and
Wang K: Extracellular microRNA: A new source of biomarkers. Mutat
Res. 717:85–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferracin M, Veronese A and Negrini M:
Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev
Mol Diagn. 10:297–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gilad S, Meiri E, Yogev Y, Benjamin S,
Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed
N, et al: Serum microRNAs are promising novel biomarkers. PLoS One.
3:e31482008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang MH and Reynolds CP: Bcl-2 inhibitors:
Targeting mitochondrial apoptotic pathways in cancer therapy. Clin
Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aubert S, Wacrenier A, Leroy X, Devos P,
Carnaille B, Proye C, Wemeau JL, Lecomte-Houcke M and Leteurtre E:
Weiss system revisited: A clinicopathologic and immunohistochemical
study of 49 adrenocortical tumors. Am J Surg Pathol. 26:1612–1619.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang B, Li Z, Zhang W, Wang H, Zhi X,
Feng J, Chen Z, Zhu Y, Yang L, Xu H, et al: miR-874 inhibits cell
proliferation, migration and invasion through targeting aquaporin-3
in gastric cancer. J Gastroenterol. 49:1011–1025. 2014. View Article : Google Scholar
|
|
16
|
Chehrehasa F, Meedeniya AC, Dwyer P,
Abrahamsen G and Mackay-Sim A: EdU, a new thymidine analogue for
labelling proliferating cells in the nervous system. J Neurosci
Methods. 177:122–130. 2009. View Article : Google Scholar
|
|
17
|
Skommer J, Brittain T and Raychaudhuri S:
Bcl-2 inhibits apoptosis by increasing the time-to-death and
intrinsic cell-to-cell variations in the mitochondrial pathway of
cell death. Apoptosis. 15:1223–1233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suzuki H, Maruyama R, Yamamoto E and Kai
M: DNA methylation and microRNA dysregulation in cancer. Mol Oncol.
6:567–578. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Soon PS, Tacon LJ, Gill AJ, Bambach CP,
Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson
BG, et al: miR-195 and miR-483–5p identified as predictors of poor
prognosis in adrenocortical cancer. Clin Cancer Res. 15:7684–7692.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fassina A, Cappellesso R, Guzzardo V,
Dalla Via L, Piccolo S, Ventura L and Fassan M:
Epithelial-mesenchymal transition in malignant mesothelioma. Mod
Pathol. 25:86–99. 2012. View Article : Google Scholar
|
|
22
|
Greene SB, Herschkowitz JI and Rosen JM:
The ups and downs of miR-205: Identifying the roles of miR-205 in
mammary gland development and breast cancer. RNA Biol. 7:300–304.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu J, Ryan DG, Getsios S,
Oliveira-Fernandes M, Fatima A and Lavker RM: MicroRNA-184
antagonizes microRNA-205 to maintain SHIP2 levels in epithelia.
Proc Natl Acad Sci USA. 105:19300–19305. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Iorio MV, Casalini P, Piovan C, Di Leva G,
Merlo A, Triulzi T, Ménard S, Croce CM and Tagliabue E:
microRNA-205 regulates HER3 in human breast cancer. Cancer Res.
69:2195–2200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gandellini P, Folini M, Longoni N, Pennati
M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta
P, et al: miR-205 exerts tumor-suppressive functions in human
prostate through downregulation of protein kinase Cepsilon. Cancer
Res. 69:2287–2295. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu H, Zhu S and Mo YY: Suppression of cell
growth and invasion by miR-205 in breast cancer. Cell Res.
19:439–448. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Verdoodt B, Neid M, Vogt M, Kuhn V,
Liffers ST, Palisaar RJ, Noldus J, Tannapfel A and
Mirmohammadsadegh A: MicroRNA-205, a novel regulator of the
anti-apoptotic protein Bcl2, is downregulated in prostate cancer.
Int J Oncol. 43:307–314. 2013.PubMed/NCBI
|
|
29
|
Mesiano S and Jaffe RB: Role of growth
factors in the developmental regulation of the human fetal adrenal
cortex. Steroids. 62:62–72. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
West AN, Neale GA, Pounds S, Figueredo BC,
Rodriguez Galindo C, Pianovski MA, Oliveira Filho AG, Malkin D,
Lalli E, Ribeiro R, et al: Gene expression profiling of childhood
adrenocortical tumors. Cancer Res. 67:600–608. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Spencer SJ, Mesiano S, Lee JY and Jaffe
RB: Proliferation and apoptosis in the human adrenal cortex during
the fetal and perinatal periods: Implications for growth and
remodeling. J Clin Endocrinol Metab. 84:1110–1115. 1999.PubMed/NCBI
|
|
32
|
Coulter CLL: Fetal adrenal development:
Insight gained from adrenal tumors. Trends Endocrinol Metab.
16:235–242. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
El Wakil A, Doghman M, Latre De Late P,
Zambetti GP, Figueiredo BC and Lalli E: Genetics and genomics of
childhood adrenocortical tumors. Mol Cell Endocrinol. 336:169–173.
2011. View Article : Google Scholar
|
|
34
|
Plati J, Bucur O and Khosravi-Far R:
Apoptotic cell signaling in cancer progression and therapy. Integr
Biol Camb. 3:279–296. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fonseca AL, Kugelberg J, Starker LF,
Scholl U, Choi M, Hellman P, Åkerström G, Westin G, Lifton RP,
Björklund P, et al: Comprehensive DNA methylation analysis of
benign and malignant adrenocortical tumors. Genes Chromosomes
Cancer. 51:949–960. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cimmino A, Calin GA, Fabbri M, Iorio MV,
Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et
al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng
H and Lai M: MiR-148a promotes apoptosis by targeting Bcl-2 in
colorectal cancer. Cell Death Differ. 18:1702–1710. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhu W, Shan X, Wang T, Shu Y and Liu P:
miR-181b modulates multidrug resistance by targeting BCL2 in human
cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
